Natalizumab in Multiple Sclerosis: Long-Term Management

Natalizumab is a monoclonal antibody highly effective in the treatment of relapsing remitting multiple sclerosis (RRMS) patients. Despite its effectiveness, there are growing concerns regarding the risk of progressive multifocal leukoencephalopathy (PML), a brain infection caused by John Cunningham...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Int J Mol Sci
Autors principals: Clerico, Marinella, Artusi, Carlo Alberto, Di Liberto, Alessandra, Rolla, Simona, Bardina, Valentina, Barbero, Pierangelo, De Mercanti, Stefania Federica, Durelli, Luca
Format: Artigo
Idioma:Inglês
Publicat: MDPI 2017
Matèries:
Review
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5454853/
https://ncbi.nlm.nih.gov/pubmed/28468254
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/ijms18050940
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars